Share:
Solensia is the first injectable monoclonal antibody (mAb) licensed for alleviation of pain associated with osteoarthritis (OA) in cats
Solensia works as a monthly treatment targeting Nerve Growth Factor (NGF), a key player in OA pain
European Commission Marketing Authorization for a similar product in dogs, Librela
®,
was received in November 2020
Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia
® (frunevetmab), a new feline osteoarthritis treatment to alleviate pain. Osteoarthritis in cats is a very prevalent condition
1, existing in 40% of cats, and may generate pain and limit a cat s comfort and quality of life if not treated.
Zoetis Inc.: Zoetis Receives European Commission Marketing Authorization for Solensia (frunevetmab), a New Therapy for Feline Osteoarthritis Pain
Solensia works as a monthly treatment targeting Nerve Growth Factor (NGF), a key player in OA pain
European Commission Marketing Authorization for a similar product in dogs, Librela
,
was received in November 2020 Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia (frunevetmab), a new feline osteoarthritis treatment to alleviate pain. Osteoarthritis in cats is a very prevalent condition
1, existing in 40% of cats, and may generate pain and limit a cat s comfort and quality of life if not treated.